Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Matthias Schomber on November 18th, 2026 | 05:36 CET

A three-way look: What Allianz shareholders, BioNTech investors and HPQ Silicon speculators should know now!

  • biotech
  • cancer drugs
  • cancer pipeline
  • coronavirus
  • vaccination
  • mrna
  • battery
  • rechargeable battery
  • rechargeable battery technology
  • battery cells
  • rechargeable battery cell
  • nanotechnology
  • drones
  • drone technology
  • insurance
  • insurance business

Created and published on behalf of HPQ Silicon
Allianz is delivering impressive record results. Vaccine specialist BioNTech continues to advance its oncology pipeline. Canadian small-cap HPQ Silicon may once again be on the verge of a promising technical breakout, as it was several years ago. Whether it is fundamental strength in the insurance sector, billion-dollar research bets in biotech and cancer drugs or speculative technology potential in batteries and energy storage, the following sections examine the opportunities, risks and financial data of these three very different stocks, providing investors with valuable guidance for their next strategic portfolio decisions.

Read

Commented by Matthias Schomber on October 30th, 2026 | 05:27 CET

BioNTech seeks a breakthrough with its cancer pipeline, DroneShield battles short sellers and Cardiol Therapeutics targets a rebound!

  • biotech
  • rebound
  • technical analysis
  • droneshield
  • biontech
  • cardiol
  • therapeutics
  • moderna
  • cancer
  • pipeline

Created and published on behalf of Cardiol Therapeutics

Biotech heavyweights such as BioNTech and defence and drone stocks such as DroneShield are currently looking for unambiguous and clear trend signals. While BioNTech is grappling with clinical setbacks and internal discussions despite strategic collaborations, defence specialist DroneShield is weighed down by persistent short-selling pressure and rather subdued growth expectations. At the same time, Cardiol Therapeutics is coming into focus as a technically promising candidate that, following a correction lasting several months, could now find the long-awaited bottom at a prominent technical support zone. This equity analysis of the 3 stocks examines the financial data, operational milestones and strategic opportunities as well as the risks of the three companies to provide guidance that is as well-founded as possible. Read on to find out where attractive opportunities are now emerging.

Read

Commented by Stefan Feulner on October 22nd, 2026 | 05:25 CEST

BioNTech, Formycon, Biogen: Pharma billions are being redistributed

  • Biotechnology

The pharmaceutical industry is facing a massive restructuring. As blockbuster drugs worth billions lose patent exclusivity, cheaper copycat products are entering the market. At the same time, biotech groups are investing billions in new cancer drugs and therapies for diseases that have long been difficult to treat. For investors, this creates tension between established revenue generators, new active ingredients and rising healthcare costs. Companies that secure access to lucrative drug markets early are particularly interesting. Even a small share of a global blockbuster's revenue can have considerable economic significance.

Read

Commented by Tarik Dede on October 15th, 2026 | 05:29 CEST

McDonald’s, dynaCERT and BioNTech: The News Moving Stock Prices

  • McDonalds
  • dynaCERT
  • BioNTech
  • Burger
  • Diesel
  • Cancer

On the stock market, guilt by association is often the rule. Recently, chip stocks came under pressure, particularly in South Korea’s Kospi, even though semiconductor stocks there trade at significantly lower valuations than their counterparts in New York. Yet beyond concerns over interest rates and geopolitical tensions, inflation data or escalating trade disputes, it is worth taking a closer look at individual stocks. After all, operational developments tend to shape earnings and share price performance over the medium to long term. That is why today we are taking a closer look at McDonald’s, dynaCERT and BioNTech.

Read

Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST

Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?

  • Biotechnology
  • Biotech
  • ODF
  • weightloss

The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?

Read

Commented by Fabian Lorenz on October 2nd, 2026 | 06:55 CEST

BioNTech: A Setback or a Breakthrough? Micron and Volatus Aerospace Impress with Positive News Flow!

  • Drones
  • Defense
  • hightech
  • Biotechnology
  • AI

Contrarian investors, take note! An exciting opportunity may currently be emerging at Volatus Aerospace. Drone stocks continue to struggle on the stock market. However, the industry's long-term outlook remains positive in both the military and civilian sectors. While Volatus shares are consolidating, positive news continues to flow with new orders and technological advances. Micron Technology has also delivered strong news. Its record figures for 2026 exceeded estimates. The outlook is also positive. Can this dispel investors' skepticism regarding the sustainability of growth and margins? A sign of weakness or a bold move? This question arises with BioNTech in light of the permanent closure of three sites. The media response has been largely critical. However, there are also positive comments.

Read

Commented by Fabian Lorenz on September 21st, 2026 | 07:45 CEST

Following Stock-Market Legend André Kostolany: Are Siemens Energy, BioNTech or HPQ Silicon Contrarian Plays?

  • Silicon
  • Batteries
  • Energy
  • Biotechnology
  • FumedSilica

Contrarian investors, take note! The stock market does not always behave rationally. Stock-market legend André Kostolany liked to compare the relationship between a company's performance and its share price to a man out for a walk with his dog. Sometimes the dog runs ahead, sometimes it lags behind, but ultimately both move in the same direction. HPQ Silicon appears to be a case in point. While the company has been releasing one positive announcement after another, its stock has come under pressure. This discrepancy is precisely what makes the stock interesting for contrarian investors. Siemens Energy presents almost the opposite picture. The stock has already priced in a great deal of growth, while analysts are recommending a "Sell". And what about BioNTech?

Read

Commented by Matthias Schomber on September 17th, 2026 | 07:20 CEST

Jungheinrich, BioNTech and Almonty Industries: The Hidden Comeback Opportunities for Your Portfolio

  • Tungsten
  • CriticalMetals
  • Defense
  • Biotechnology

The market environment is currently rather weak, characterized by slightly falling share prices across the stock markets. In the commodities markets, however, especially in oil, prices are rising slightly to more sharply, by contrast. Investors are getting increasingly nervous, a trend also reflected in bond yields. Yet it is precisely in such phases, when nervousness takes over and many market participants throw in the towel, that attractive entry opportunities can emerge for savvy investors. That is why today we are looking at three very different companies that nevertheless have one thing in common: they could be heading for a rebound or an upward move. With BioNTech, we look at a company focused on the oncology sector. Jungheinrich takes us into the world of warehouse logistics and mechanical engineering — a genuine industry veteran. Finally, we turn to Almonty. The company was once a hidden gem in the commodities sector. That is no longer the case, however: given its strategic importance to the Western defence industry, it has become increasingly difficult to overlook. Join us on an analytical journey through financial statements and charts to discover where interesting opportunities may arise in terms of risk and return.

Read

Commented by Jens Castner on September 16th, 2026 | 06:50 CEST

Tungsten, Beer and Vaccines: What Almonty Industries, Heineken and BioNTech Have in Common

  • Tungsten
  • Beer
  • Beverages
  • Biotech

A commodities company whose share price has tripled in a single year because an unassuming heavy metal has become a sought-after, scarce commodity. A brewing giant that has been operating a cash cow in Africa for decades and has a clear strategy for increasing margins. A pharmaceutical pioneer writing its next chapter after the end of the COVID boom—with a factory that literally consists of shipping containers. At first glance, Almonty Industries, Heineken and BioNTech do not have much in common. But upon closer inspection, all three are betting on the same underrated market. Here is how you, as an investor, can benefit.

Read

Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST

New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention

  • Biotech
  • Biotechnology
  • Cancer
  • Pharma

Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?

Read